Glioblastoma Multiforme News and Research

RSS

Glioblastoma Multiforme is a fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. Glioblastoma multiforme usually occurs in adults and affects the brain more often than the spinal cord. Also called GBM, glioblastoma, and grade IV astrocytoma.

ELTD1 biomarker may help diagnose glioma

Researchers using sophisticated genetic testing techniques have identified a promising new biomarker for diagnosis of glioma—the most common type of malignant brain tumor, reports the January issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

17 Jan 2013

Research: Smaller radiation fields can effectively treat aggressive brain tumors

New research from Wake Forest Baptist Medical Center shows that patients suffering from aggressive brain tumors can be effectively treated with smaller radiation fields to spare the rest of the brain and preserve cognition.

11 Jan 2013

Researchers identify 125 genetic components in temozolomide-resistant, GBM-derived cell line

University of Pittsburgh Cancer Institute (UPCI) researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line, which could offer new hope for drug treatment to destroy the cancer cells.

15 Dec 2012

Paper illuminates importance of PKM2 in cancer development and progression

Researchers at The University of Texas MD Anderson Cancer Center have tracked down a cancer-promoting protein's pathway into the cell nucleus and discovered how, once there, it fires up a glucose metabolism pathway on which brain tumors thrive.

26 Nov 2012

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Genentech, a member of the Roche Group, today announced results from the positive Phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo>th Annual Meeting of the Society for Neuro-Oncology in Washington, D.C.

19 Nov 2012

Glioblastoma multiforme can originate from cortical neurons

Scientists have long believed that glioblastoma multiforme (GBM), the most aggressive type of primary brain tumor, begins in glial cells that make up supportive tissue in the brain or in neural stem cells. In a paper published October 18 in Science Express, however, researchers at the Salk Institute for Biological Studies have found that the tumors can originate from other types of differentiated cells in the nervous system, including cortical neurons.

23 Oct 2012

UCI neuro-oncologist to lead DCVax Phase II trial in glioblastoma multiforme

UC Irvine doctors are enrolling patients with the deadly brain tumor glioblastoma multiforme in a clinical trial of a vaccine that may prevent the cancer's return or spread after surgery.

11 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

Elevated c-Myc expression amplifies gene activity in tumor cells of multiple cancer types

For a cancer patient, over-expression of the MYC oncogene is a bad omen. Scientists have long known that in tumor cells, elevated levels of MYC's protein product, c-Myc, are associated with poor clinical outcomes, including increased rates of metastasis, recurrence, and mortality. Yet decades of research producing thousands of scientific papers on the subject have failed to consistently explain precisely how c-Myc exerts its effects across a broad range of cancer types. Until now, that is.

28 Sep 2012

Scientists identify master regulator essential for progression and relapse of deadly brain cancer

A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults- glioblastoma multiforme. The scientists found that by targeting this biomarker and depleting it with a potential drug, they were able to prevent the progression and relapse of the brain tumour.

5 Sep 2012

Patients tend to have worse outcomes when GBM appears in more than one location

When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.

27 Aug 2012

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Northwest Biotherapeutics announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, for the Company's 300-patient Phase III clinical trial of DCVax-L immune therapy for Glioblastoma multiforme brain cancer (GBM) to proceed in the U.K.

24 Aug 2012

Pyruvate kinase M2 fuels tumor growth by influencing H3 histone protein

A metabolic protein that nourishes cancer cells also activates tumor-promoting genes by loosening part of the packaging that entwines DNA to make up chromosomes, a team led by scientists at The University of Texas MD Anderson Cancer Center reports in the Aug. 16 issue of Cell.

17 Aug 2012

Passenger deletions that deactivate essential genes provide new opportunity to strike cancer

Genomic deletions promote cancer by carving up or eliminating tumor-suppressor genes, but now scientists report in the journal Nature that the collateral damage they inflict on neighboring genes exposes cancer cells to vulnerabilities and new avenues for attack.

16 Aug 2012

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

ImmunoCellular Therapeutics announced today that clinical data from its Phase I trial of ICT-107 was accepted for publication, and is currently in the online edition of the prestigious medical journal Cancer Immunology, Immunotherapy.

9 Aug 2012

New insight into why glioblastoma multiforme recurs in adults

A study by UT Southwestern Medical Center researchers published online today in Nature reveals new insight into why the most common, deadly kind of brain tumor in adults recurs and identifies a potential target for future therapies.

2 Aug 2012

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.

26 Jul 2012

NBTI participates in ICT-107 phase II trial for glioblastoma multiforme

Researchers at Northwestern Brain Tumor Institute (NBTI) are seeking to understand if a vaccine made from a patient's own blood cells may slow the growth of a type of brain tumor.

25 Jul 2012

LSDF announces $570,000 in awards to support commercialization of new health-related products

The Life Sciences Discovery Fund (LSDF) today announced nearly $570,000 in awards in its inaugural corporate grant program to support commercialization of new health and health-care products by four early-stage Washington-based companies.

25 Jul 2012

Ampio announces advancement of NCE001 to preclinical development

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.

17 Jul 2012

Glioblastoma Multiforme News and Research

ELTD1 biomarker may help diagnose glioma

Research: Smaller radiation fields can effectively treat aggressive brain tumors

Researchers identify 125 genetic components in temozolomide-resistant, GBM-derived cell line

Paper illuminates importance of PKM2 in cancer development and progression

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Glioblastoma multiforme can originate from cortical neurons

UCI neuro-oncologist to lead DCVax Phase II trial in glioblastoma multiforme

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Elevated c-Myc expression amplifies gene activity in tumor cells of multiple cancer types

Scientists identify master regulator essential for progression and relapse of deadly brain cancer

Patients tend to have worse outcomes when GBM appears in more than one location

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Pyruvate kinase M2 fuels tumor growth by influencing H3 histone protein

Passenger deletions that deactivate essential genes provide new opportunity to strike cancer

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

New insight into why glioblastoma multiforme recurs in adults

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

NBTI participates in ICT-107 phase II trial for glioblastoma multiforme

LSDF announces $570,000 in awards to support commercialization of new health-related products

Ampio announces advancement of NCE001 to preclinical development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News